Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers
Latest Information Update: 03 Jun 2025
At a glance
- Drugs Cisplatin (Primary) ; Nivolumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Jan 2025 Status changed from active, no longer recruiting to completed.
- 30 Jul 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2026.
- 30 Jul 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Apr 2026.